Loading...

iAnthus Capital Holdings, Inc.

IAN.CNCNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.005
CA$0.00(0.00%)

iAnthus Capital Holdings, Inc. (IAN.CN) Financial Performance & Income Statement Overview

Review iAnthus Capital Holdings, Inc. (IAN.CN) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
5.23%
5.23%
Operating Income Growth
79.09%
79.09%
Net Income Growth
90.03%
90.03%
Operating Cash Flow Growth
315.78%
315.78%
Operating Margin
-6.85%
6.85%
Gross Margin
46.22%
46.22%
Net Profit Margin
1.65%
1.65%
ROE
-3.48%
3.48%
ROIC
-5.65%
5.65%

iAnthus Capital Holdings, Inc. (IAN.CN) Income Statement & Financial Overview

Access detailed annual and quarterly income data for iAnthus Capital Holdings, Inc. IAN.CN financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$38.12M$42.72M$40.29M$43.00M
Cost of Revenue$19.24M$23.58M$22.20M$22.31M
Gross Profit$18.88M$19.14M$18.08M$20.69M
Gross Profit Ratio$0.50$0.45$0.45$0.48
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$16.82M$15.17M$15.15M$14.90M
Operating Expenses$16.82M$21.21M$19.34M$20.91M
Total Costs & Expenses$36.06M$43.55M$41.54M$43.22M
Interest Income$0.00$906000.00$817000.00$2.78M
Interest Expense-$4.21M$5.63M$5.54M$5.41M
Depreciation & Amortization$4.22M$6.04M$6.12M$6.20M
EBITDA$9.17M$4.73M$5.66M$5.98M
EBITDA Ratio$0.24$0.11$0.14$0.14
Operating Income-$2.01M-$2.07M-$1.26M-$225000.00
Operating Income Ratio-$0.05-$0.05-$0.03-$0.005
Other Income/Expenses (Net)$11.17M-$4.74M-$4.74M-$2.64M
Income Before Tax$9.16M-$6.81M-$6.00M-$2.87M
Income Before Tax Ratio$0.24-$0.16-$0.15-$0.07
Income Tax Expense$4.009M-$34.60M$5.64M$6.92M
Net Income$5.15M$27.73M-$11.64M-$9.79M
Net Income Ratio$0.14$0.65-$0.29-$0.23
EPS$0.001$0.004-$0.002-$0.002
Diluted EPS$0.001$0.004-$0.002-$0.002
Weighted Avg Shares Outstanding$6.74B$6.54B$6.52B$6.51B
Weighted Avg Shares Outstanding (Diluted)$6.74B$6.54B$6.52B$6.51B

Over the last four quarters, iAnthus Capital Holdings, Inc. achieved steady financial progress, growing revenue from $43.00M in Q2 2024 to $38.12M in Q1 2025. Gross profit stayed firm with margins at 50% in Q1 2025 versus 48% in Q2 2024. Operating income totaled -$2.01M in Q1 2025, maintaining a -5% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $9.17M. Net income dropped to $5.15M, with EPS at $0.001. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;